The response to the COVID-19 pandemic has included unprecedented measures to slow the spread of the virus taken by local governments and health care authorities globally, including the postponement of deferrable medical procedures and social contact restrictions, which have had a significant negative impact on our operations and financial results.
Kalamazoo, Michigan, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2020:
The response to the COVID-19 pandemic has included unprecedented measures to slow the spread of the virus taken by local governments and health care authorities globally, including the postponement of deferrable medical procedures and social contact restrictions, which have had a significant negative impact on our operations and financial results.
Third Quarter Results
- Reported net sales increased 4.2% to $3.7 billion
- Organic net sales increased 3.3%
- Reported operating income margin of 23.0%
- Adjusted operating income margin(1) expanded 260 bps to 28.0%
- Reported EPS increased 32.5% to $1.63
- Adjusted EPS(1) increased 12.0% to $2.14
| Third Quarter Net Sales Growth Overview | ||||||||||||||
| Reported | Foreign Currency Exchange | Constant Currency | Acquisitions | Organic | ||||||||||
| Orthopaedics | 4.4 | % | 0.6 | % | 3.8 | % | — | % | 3.8 | % | ||||
| MedSurg | 3.2 | 0.3 | 2.9 | 0.4 | 2.5 | |||||||||
| Neurotechnology and Spine | 6.0 | 0.5 | 5.5 | 1.2 | 4.3 | |||||||||
| Total | 4.2 | % | 0.4 | % | 3.8 | % | 0.5 | % | 3.3 | % | ||||
“We are pleased to have returned to growth in the third quarter and delivered strong adjusted earnings and cash flow in a challenging environment,” said Kevin A. Lobo, Chairman and Chief Executive Officer. “Our teams executed well in serving our customers, advancing innovations and preparing for the Wright Medical integration.”
Sales Analysis
Consolidated net sales of $3.7 billion increased 4.2% in the quarter and 3.8% in constant currency. Organic net sales increased 3.3% in the quarter including 4.7% from increased unit volume partially offset by 1.4% from lower prices.
Orthopaedics net sales of $1.3 billion increased 4.4% in the quarter and 3.8% in constant currency. Organic net sales increased 3.8% in the quarter including 5.9% from increased unit volume partially offset by 2.1% from lower prices.
MedSurg net sales of $1.6 billion increased 3.2% in the quarter and 2.9% in constant currency. Organic net sales increased 2.5% in the quarter including 3.1% from increased unit volume partially offset by 0.6% from lower prices.
Neurotechnology and Spine net sales of $0.8 billion increased 6.0% in the quarter and 5.5% in constant currency. Organic net sales increased 4.3% in the quarter including 6.0% from increased unit volume partially offset by 1.7% from lower prices.
Earnings Analysis
Despite the negative impacts of the global response to the COVID-19 pandemic, reported net earnings of $621 million increased 33.3% in the quarter. Reported net earnings per diluted share of $1.63 increased 32.5% in the quarter. Reported gross profit margin and reported operating income margin were 65.9% and 23.0% in the quarter. Adjusted gross profit margin(1) and adjusted operating income margin(1) were 65.9% and 28.0%, an improvement of 260 basis points in the quarter. Adjusted net earnings(1) of $812 million increased 12.0% in the quarter. Adjusted net earnings per diluted share(1) of $2.14 increased 12.0% in the quarter.
2020 Outlook
While we are still recovering from the impacts of the COVID-19 pandemic, most of our businesses reported overall increased unit volume during the third quarter. However, due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, we are unable to estimate the overall impacts on our operations and financial results, which could be material. Accordingly, we will not be providing fourth quarter or full-year organic sales growth or earnings guidance for 2020.
(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.
Conference Call on October 29, 2020
As previously announced, Stryker will host a conference call on Thursday, October 29, 2020 at 4:30 p.m., Eastern Time, to discuss the Company’s operating results for the quarter ended September 30, 2020 and provide an operational update.
To participate in the conference call dial (877) 702-4565 (domestic) or (647) 689-5532 (international) and be prepared to provide conference ID number 5297589 to the operator.
A simultaneous webcast of the call will be accessible via the Company’s website at www.stryker.com. The call will be archived on the Investor Relations page of this site.
A recording of the call will also be available from 8:00 p.m., Eastern Time, on Thursday, October 29, 2020, until 11:59 p.m., Eastern Time, on Thursday, November 5, 2020. To hear this recording, you may dial (800) 585-8367 (domestic) or (416) 621-4642 (international) and enter conference ID number 5297589.
Caution Concerning Forward-Looking Statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: the impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties; the failure to satisfy any of the closing conditions to the acquisition of Wright Medical Group N.V. (“Wright”), including the receipt of any required regulatory clearances (and the risk that such clearances may result in the imposition of conditions that could adversely affect the expected benefits of the transaction); timing of the closing of the acquisition of Wright; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright; the effects of the proposed Wright transaction (or the announcement thereof) on the parties’ relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.
For investor inquiries please contact:
Preston Wells, Vice President, Investor Relations at 269-385-2600 or preston.wells@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com
| STRYKER CORPORATION | |||||||||||||||||||||||||||
| For the Three and Nine Months September 30 | |||||||||||||||||||||||||||
| (Unaudited - Millions of Dollars, Except Per Share Amounts) | |||||||||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF EARNINGS | |||||||||||||||||||||||||||
| Three Months | Nine Months | ||||||||||||||||||||||||||
| 2020 | 2019 | % Change | 2020 | 2019 | % Change | ||||||||||||||||||||||
| Net sales | $ | 3,737 | $ | 3,587 | 4.2 | % | $ | 10,089 | $ | 10,753 | (6.2 | ) | % | ||||||||||||||
| Cost of sales | 1,276 | 1,257 | 1.5 | 3,749 | 3,760 | (0.3 | ) | ||||||||||||||||||||
| Gross profit | $ | 2,461 | $ | 2,330 | 5.6 | % | $ | 6,340 | $ | 6,993 | (9.3 | ) | % | ||||||||||||||
| % of sales | 65.9 | % | 65.0 | % | 62.8 | % | 65.0 | % | |||||||||||||||||||
| Research, development and engineering expenses | 242 | 246 | (1.6 | ) | 729 | 717 | 1.7 | ||||||||||||||||||||
| Selling, general and administrative expenses | 1,244 | 1,291 | (3.6 | ) | 3,799 | 3,976 | (4.5 | ) | |||||||||||||||||||
| Recall charges | 2 | 49 | (95.9 | ) | (4 | ) | 179 | nm | |||||||||||||||||||
| Amortization of intangible assets | 114 | 116 | (1.7 | ) | 342 | 352 | (2.8 | ) | |||||||||||||||||||
| Total operating expenses | $ | 1,602 | $ | 1,702 | (5.9 | ) | % | $ | 4,866 | $ | 5,224 | (6.9 | ) | % | |||||||||||||
| Operating income | $ | 859 | $ | 628 | 36.8 | % | $ | 1,474 | $ | 1,769 | (16.7 | ) | % | ||||||||||||||
| % of sales | 23.0 | % | 17.5 | % | 14.6 | % | 16.5 | % | |||||||||||||||||||
| Other income (expense), net | (79 | ) | (47 | ) | 68.1 | (191 | ) | (143 | ) | 33.6 | |||||||||||||||||
| Earnings before income taxes | $ | 780 | $ | 581 | 34.3 | % | $ | 1,283 | $ | 1,626 | (21.1 | ) | % | ||||||||||||||
| Income taxes | 159 | 115 | 38.3 | 252 | 268 | (6.0 | ) | ||||||||||||||||||||
| Net earnings | $ | 621 | $ | 466 | 33.3 | % | $ | 1,031 | $ | 1,358 | (24.1 | ) | % | ||||||||||||||
| Net earnings per share of common stock: | |||||||||||||||||||||||||||
| Basic | $ | 1.66 | $ | 1.24 | 33.9 | % | $ | 2.75 | $ | 3.63 | (24.2 | ) | % | ||||||||||||||
| Diluted | $ | 1.63 | $ | 1.23 | 32.5 | % | $ | 2.71 | $ | 3.58 | (24.3 | ) | % | ||||||||||||||
| Weighted-average shares outstanding (in millions): | |||||||||||||||||||||||||||
| Basic | 375.7 | 374.2 | 375.3 | 373.8 | |||||||||||||||||||||||
| Diluted | 380.2 | 380.3 | 380.0 | 379.8 | |||||||||||||||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| September 30 | December 31 | ||||||
| 2020 | 2019 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 7,083 | $ | 4,337 | |||
| Marketable securities | 78 | 88 | |||||
| Accounts receivable, net | 2,426 | 2,893 | |||||
| Inventories | 3,459 | 3,282 | |||||
| Prepaid expenses and other current assets | 499 | 760 | |||||
| Total current assets | $ | 13,545 | $ | 11,360 | |||
| Property, plant and equipment, net | 2,529 | 2,567 | |||||
| Goodwill and other intangibles, net | 13,045 | 13,296 | |||||
| Noncurrent deferred income tax assets | 1,627 | 1,575 | |||||
| Other noncurrent assets | 1,540 | 1,369 | |||||
| Total assets | $ | 32,286 | $ | 30,167 | |||
| Liabilities and shareholders’ equity | |||||||
| Current liabilities | $ | 4,689 | $ | 4,400 | |||
| Long-term debt, excluding current maturities | 12,008 | 10,231 | |||||
| Income taxes | 999 | 1,068 | |||||
| Other noncurrent liabilities | 1,604 | 1,661 | |||||
| Shareholders’ equity | 12,986 | 12,807 | |||||
| Total liabilities and shareholders’ equity | $ | 32,286 | $ | 30,167 | |||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| Nine Months | |||||||||
| 2020 | 2019 | ||||||||
| Operating activities | |||||||||
| Net earnings | $ | 1,031 | $ | 1,358 | |||||
| Depreciation | 247 | 231 | |||||||
| Amortization of intangible assets | 342 | 352 | |||||||
| Changes in operating assets, liabilities, income taxes payable and other, net | 420 | (485 | ) | ||||||
| Net cash provided by operating activities | $ | 2,040 | $ | 1,456 | |||||
| Investing activities | |||||||||
| Acquisitions, net of cash acquired | $ | (26 | ) | $ | (281 | ) | |||
| Change in marketable securities, net | 10 | (5 | ) | ||||||
| Purchases of property, plant and equipment | (322 | ) | (450 | ) | |||||
| Other investing, net | (11 | ) | — | ||||||
| Net cash used in investing activities | $ | (349 | ) | $ | (736 | ) | |||
| Financing activities | |||||||||
| Borrowings (payments) of debt, net | $ | 1,796 | $ | (1,348 | ) | ||||
| Dividends paid | (647 | ) | (585 | ) | |||||
| Repurchases of common stock | — | (307 | ) | ||||||
| Other financing, net | (103 | ) | (120 | ) | |||||
| Net cash provided by (used in) financing activities | $ | 1,046 | $ | (2,360 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents | 9 | (28 | ) | ||||||
| Change in cash and cash equivalents | $ | 2,746 | $ | (1,668 | ) | ||||
nm - not meaningful
| STRYKER CORPORATION |
| For the Three and Nine Months September 30 |
| (Unaudited - Millions of Dollars) |
| SALES GROWTH ANALYSIS | |||||||||||||||||||||||||||
| Three Months | Nine Months | ||||||||||||||||||||||||||
| Percentage Change | Percentage Change | ||||||||||||||||||||||||||
| 2020 | 2019 | As Reported | Constant Currency | 2020 | 2019 | As Reported | Constant Currency | ||||||||||||||||||||
| Geographic: | |||||||||||||||||||||||||||
| United States | $ | 2,748 | $ | 2,644 | 3.9 | % | 3.9 | % | $ | 7,357 | $ | 7,918 | (7.1 | ) | % | (7.1 | ) | % | |||||||||
| International | 989 | 943 | 5.0 | 3.3 | 2,732 | 2,835 | (3.6 | ) | (2.1 | ) | |||||||||||||||||
| Total | $ | 3,737 | $ | 3,587 | 4.2 | % | 3.8 | % | $ | 10,089 | $ | 10,753 | (6.2 | ) | % | (5.8 | ) | % | |||||||||
| Segment: | |||||||||||||||||||||||||||
| Orthopaedics | $ | 1,317 | $ | 1,262 | 4.4 | % | 3.8 | % | $ | 3,433 | $ | 3,785 | (9.3 | ) | % | (9.0 | ) | % | |||||||||
| MedSurg | 1,600 | 1,552 | 3.2 | 2.9 | 4,546 | 4,680 | (2.9 | ) | (2.4 | ) | |||||||||||||||||
| Neurotechnology and Spine | 820 | 773 | 6.0 | 5.5 | 2,110 | 2,288 | (7.8 | ) | (7.4 | ) | |||||||||||||||||
| Total | $ | 3,737 | $ | 3,587 | 4.2 | % | 3.8 | % | $ | 10,089 | $ | 10,753 | (6.2 | ) | % | (5.8 | ) | % | |||||||||
| SUPPLEMENTAL SALES GROWTH ANALYSIS | |||||||||||||||||||||||||
| Three Months | |||||||||||||||||||||||||
| United States | International | ||||||||||||||||||||||||
| Percentage Change | |||||||||||||||||||||||||
| 2020 | 2019 | As Reported | Constant Currency | As Reported | As Reported | Constant Currency | |||||||||||||||||||
| Orthopaedics: | |||||||||||||||||||||||||
| Knees | $ | 435 | $ | 426 | 2.2 | % | 1.7 | % | 4.6 | % | (4.8 | ) | % | (6.9 | ) | % | |||||||||
| Hips | 334 | 332 | 0.4 | (0.1 | ) | 5.3 | (8.2 | ) | (9.7 | ) | |||||||||||||||
| Trauma and Extremities | 430 | 407 | 5.6 | 4.7 | 9.0 | (0.5 | ) | (3.0 | ) | ||||||||||||||||
| Other | 118 | 97 | 22.5 | 22.2 | 20.0 | 34.9 | 33.0 | ||||||||||||||||||
| $ | 1,317 | $ | 1,262 | 4.4 | % | 3.8 | % | 7.5 | % | (2.6 | ) | % | (4.7 | ) | % | ||||||||||
| MedSurg: | |||||||||||||||||||||||||
| Instruments | $ | 467 | $ | 452 | 3.4 | % | 3.1 | % | 3.1 | % | 4.7 | % | 2.9 | % | |||||||||||
| Endoscopy | 467 | 474 | (1.3 | ) | (1.5 | ) | 1.0 | (10.1 | ) | (11.0 | ) | ||||||||||||||
| Medical | 600 | 554 | 8.3 | 8.0 | 3.0 | 29.0 | 27.8 | ||||||||||||||||||
| Sustainability | 66 | 72 | (8.7 | ) | (8.7 | ) | (8.9 | ) | nm | nm | |||||||||||||||
| $ | 1,600 | $ | 1,552 | 3.2 | % | 2.9 | % | 1.7 | % | 8.9 | % | 7.6 | % | ||||||||||||
| Neurotechnology and Spine: | |||||||||||||||||||||||||
| Neurotechnology | $ | 518 | $ | 490 | 5.7 | % | 5.1 | % | 1.9 | % | 12.6 | % | 11.1 | % | |||||||||||
| Spine | 302 | 283 | 6.6 | 6.1 | 4.9 | 11.3 | 9.6 | ||||||||||||||||||
| $ | 820 | $ | 773 | 6.0 | % | 5.5 | % | 3.1 | % | 12.2 | % | 10.6 | % | ||||||||||||
| Total | $ | 3,737 | $ | 3,587 | 4.2 | % | 3.8 | % | 3.9 | % | 5.0 | % | 3.3 | % | |||||||||||
| Nine Months | |||||||||||||||||||||||||
| United States | International | ||||||||||||||||||||||||
| Percentage Change | |||||||||||||||||||||||||
| 2020 | 2019 | As Reported | Constant Currency | As Reported | As Reported | Constant Currency | |||||||||||||||||||
| Orthopaedics: | |||||||||||||||||||||||||
| Knees | $ | 1,108 | $ | 1,305 | (15.1 | ) | % | (14.8 | ) | % | (13.4 | ) | % | (19.8 | ) | % | (18.8 | ) | % | ||||||
| Hips | 866 | 1,011 | (14.4 | ) | (13.9 | ) | (12.3 | ) | (18.1 | ) | (16.8 | ) | |||||||||||||
| Trauma and Extremities | 1,152 | 1,197 | (3.8 | ) | (3.5 | ) | (1.9 | ) | (7.1 | ) | (6.4 | ) | |||||||||||||
| Other | 307 | 272 | 13.0 | 13.1 | 17.5 | (7.5 | ) | (6.7 | ) | ||||||||||||||||
| $ | 3,433 | $ | 3,785 | (9.3 | ) | % | (9.0 | ) | % | (7.1 | ) | % | (14.2 | ) | % | (13.2 | ) | % | |||||||
| MedSurg: | |||||||||||||||||||||||||
| Instruments | $ | 1,308 | $ | 1,417 | (7.7 | ) | % | (7.4 | ) | % | (8.4 | ) | % | (5.1 | ) | % | (3.5 | ) | % | ||||||
| Endoscopy | 1,238 | 1,424 | (13.0 | ) | (12.7 | ) | (12.2 | ) | (16.4 | ) | (14.8 | ) | |||||||||||||
| Medical | 1,819 | 1,627 | 11.8 | 12.6 | 5.8 | 34.6 | 38.8 | ||||||||||||||||||
| Sustainability | 181 | 212 | (14.7 | ) | (14.7 | ) | (14.7 | ) | nm | nm | |||||||||||||||
| $ | 4,546 | $ | 4,680 | (2.9 | ) | % | (2.4 | ) | % | (5.0 | ) | % | 5.9 | % | 8.4 | % | |||||||||
| Neurotechnology and Spine: | |||||||||||||||||||||||||
| Neurotechnology | $ | 1,370 | $ | 1,443 | (5.1 | ) | % | (4.7 | ) | % | (10.2 | ) | % | 4.2 | % | 5.3 | % | ||||||||
| Spine | 740 | 845 | (12.4 | ) | (12.1 | ) | (14.8 | ) | (4.9 | ) | (3.9 | ) | |||||||||||||
| $ | 2,110 | $ | 2,288 | (7.8 | ) | % | (7.4 | ) | % | (12.1 | ) | % | 1.6 | % | 2.6 | % | |||||||||
| Total | $ | 10,089 | $ | 10,753 | (6.2 | ) | % | (5.8 | ) | % | (7.1 | ) | % | (3.6 | ) | % | (2.1 | ) | % | ||||||
SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including: percentage sales growth; percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe that these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.
To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates and acquisitions, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year results at prior year average foreign currency exchange rates excluding the impact of acquisitions. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of non-GAAP net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.
| STRYKER CORPORATION | |||||||||||||||||||||||||||
| For the Three and Nine Months September 30 | |||||||||||||||||||||||||||
| (Unaudited - Millions of Dollars, Except Per Share Amounts) | |||||||||||||||||||||||||||
| Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures | |||||||||||||||||||||||||||
| Three Months 2020 | Gross Profit | Selling, General & Administrative Expenses | Research, Development & Engineering Expenses | Operating Income | Other income (expense), net | Net Earnings | Effective Tax Rate | Diluted EPS | |||||||||||||||||||
| Reported | $ | 2,461 | $ | 1,244 | $ | 242 | $ | 859 | $ | (79 | ) | $ | 621 | 20.4 | % | $ | 1.63 | ||||||||||
| Reported percent net sales | 65.9 | % | 33.3 | % | 6.5 | % | 23.0 | % | (2.1 | ) | % | 16.6 | % | ||||||||||||||
| Acquisition and integration-related charges (a) | |||||||||||||||||||||||||||
| Inventory stepped-up to fair value | — | — | — | — | — | — | — | — | |||||||||||||||||||
| Other acquisition and integration-related | — | (29 | ) | — | 29 | — | 24 | 0.1 | 0.07 | ||||||||||||||||||
| Amortization of purchased intangible assets | — | — | — | 114 | — | 93 | 0.4 | 0.25 | |||||||||||||||||||
| Restructuring-related and other charges (b) | — | (29 | ) | — | 29 | — | 26 | (0.1 | ) | 0.06 | |||||||||||||||||
| Medical device regulations (c) | — | — | (13 | ) | 14 | — | 11 | 0.1 | 0.03 | ||||||||||||||||||
| Recall-related matters (d) | — | — | — | 2 | — | 2 | (0.2 | ) | 0.01 | ||||||||||||||||||
| Regulatory and legal matters (e) | — | — | — | — | — | — | — | — | |||||||||||||||||||
| Tax matters (f) | — | — | — | — | — | 35 | (4.6 | ) | 0.09 | ||||||||||||||||||
| Adjusted | $ | 2,461 | $ | 1,186 | $ | 229 | $ | 1,047 | $ | (79 | ) | $ | 812 | 16.1 | % | $ | 2.14 | ||||||||||
| Adjusted percent net sales | 65.9 | % | 31.7 | % | 6.1 | % | 28.0 | % | (2.1 | ) | % | 21.7 | % | ||||||||||||||
| Three Months 2019 | Gross Profit | Selling, General & Administrative Expenses | Research, Development & Engineering Expenses | Operating Income | Other income (expense), net | Net Earnings | Effective Tax Rate | Diluted EPS | |||||||||||||||||||
| Reported | $ | 2,330 | $ | 1,291 | $ | 246 | $ | 628 | $ | (47 | ) | $ | 466 | 19.8 | % | $ | 1.23 | ||||||||||
| Reported percent net sales | 65.0 | % | 36.0 | % | 6.9 | % | 17.5 | % | (1.3 | ) | % | 13.0 | % | ||||||||||||||
| Acquisition and integration-related charges (a) | |||||||||||||||||||||||||||
| Inventory stepped-up to fair value | 17 | — | — | 17 | — | 13 | 0.2 | 0.03 | |||||||||||||||||||
| Other acquisition and integration-related | — | (15 | ) | — | 15 | — | 8 | 0.6 | 0.02 | ||||||||||||||||||
| Amortization of purchased intangible assets | — | — | — | 116 | — | 105 | (1.5 | ) | 0.28 | ||||||||||||||||||
| Restructuring-related and other charges (b) | 10 | (37 | ) | — | 48 | — | 40 | 0.1 | 0.11 | ||||||||||||||||||
| Medical device regulations (c) | — | — | (15 | ) | 15 | — | 13 | — | 0.03 | ||||||||||||||||||
| Recall-related matters (d) | — | — | — | 49 | — | 28 | 2.2 | 0.07 | |||||||||||||||||||
| Regulatory and legal matters (e) | — | (25 | ) | — | 25 | — | 14 | 1.2 | 0.04 | ||||||||||||||||||
| Tax matters (f) | — | — | — | — | — | 38 | (6.5 | ) | 0.10 | ||||||||||||||||||
| Adjusted | $ | 2,357 | $ | 1,214 | $ | 231 | $ | 913 | $ | (47 | ) | $ | 725 | 16.1 | % | $ | 1.91 | ||||||||||
| Adjusted percent net sales | 65.7 | % | 33.8 | % | 6.5 | % | 25.4 | % | (1.3 | ) | % | 20.2 | % | ||||||||||||||
| Nine Months 2020 | Gross Profit | Selling, General & Administrative Expenses | Research, Development & Engineering Expenses | Operating Income | Other income (expense), net | Net Earnings | Effective Tax Rate | Diluted EPS | |||||||||||||||||||||
| Reported | $ | 6,340 | $ | 3,799 | $ | 729 | $ | 1,474 | $ | (191 | ) | $ | 1,031 | 19.6 | % | $ | 2.71 | ||||||||||||
| Reported percent net sales | 62.8 | % | 37.7 | % | 7.2 | % | 14.6 | % | (1.9 | ) | % | 10.2 | % | ||||||||||||||||
| Acquisition and integration-related charges (a) | |||||||||||||||||||||||||||||
| Inventory stepped-up to fair value | 9 | — | — | 9 | — | 6 | 0.1 | 0.02 | |||||||||||||||||||||
| Other acquisition and integration-related | — | (76 | ) | — | 76 | — | 60 | 0.4 | 0.16 | ||||||||||||||||||||
| Amortization of purchased intangible assets | — | — | — | 342 | — | 277 | 1.0 | 0.73 | |||||||||||||||||||||
| Restructuring-related and other charges (b) | 36 | (256 | ) | — | 292 | — | 238 | 0.8 | 0.62 | ||||||||||||||||||||
| Medical device regulations (c) | 1 | — | (59 | ) | 60 | — | 47 | 0.3 | 0.12 | ||||||||||||||||||||
| Recall-related matters (d) | — | — | — | (4 | ) | — | (2 | ) | (0.2 | ) | — | ||||||||||||||||||
| Regulatory and legal matters (e) | — | (5 | ) | — | 5 | — | 6 | (0.2 | ) | 0.02 | |||||||||||||||||||
| Tax matters (f) | — | — | — | — | 7 | 93 | (6.6 | ) | 0.24 | ||||||||||||||||||||
| Adjusted | $ | 6,386 | $ | 3,462 | $ | 670 | $ | 2,254 | $ | (184 | ) | $ | 1,756 | 15.2 | % | $ | 4.62 | ||||||||||||
| Adjusted percent net sales | 63.3 | % | 34.3 | % | 6.6 | % | 22.3 | % | (1.8 | ) | % | 17.4 | % | ||||||||||||||||
| Nine Months 2019 | Gross Profit | Selling, General & Administrative Expenses | Research, Development & Engineering Expenses | Operating Income | Other income (expense), net | Net Earnings | Effective Tax Rate | Diluted EPS | |||||||||||||||||||
| Reported | $ | 6,993 | $ | 3,976 | $ | 717 | $ | 1,769 | $ | (143 | ) | $ | 1,358 | 16.5 | % | $ | 3.58 | ||||||||||
| Reported percent net sales | 65.0 | % | 37.0 | % | 6.7 | % | 16.5 | % | (1.3 | ) | % | 12.6 | % | ||||||||||||||
| Acquisition and integration-related charges (a) | |||||||||||||||||||||||||||
| Inventory stepped-up to fair value | 55 | — | — | 55 | — | 42 | 0.3 | 0.11 | |||||||||||||||||||
| Other acquisition and integration-related | — | (168 | ) | — | 168 | — | 126 | 1.0 | 0.33 | ||||||||||||||||||
| Amortization of purchased intangible assets | — | — | — | 352 | — | 294 | 0.1 | 0.78 | |||||||||||||||||||
| Restructuring-related and other charges (b) | 21 | (125 | ) | — | 146 | — | 122 | 0.1 | 0.32 | ||||||||||||||||||
| Medical device regulations (c) | 1 | — | (33 | ) | 34 | — | 28 | 0.1 | 0.07 | ||||||||||||||||||
| Recall-related matters (d) | — | — | — | 179 | — | 144 | 0.4 | 0.38 | |||||||||||||||||||
| Regulatory and legal matters (e) | — | (35 | ) | — | 35 | — | 19 | 0.5 | 0.05 | ||||||||||||||||||
| Tax matters (f) | — | — | — | — | — | 58 | (3.5 | ) | 0.15 | ||||||||||||||||||
| Adjusted | $ | 7,070 | $ | 3,648 | $ | 684 | $ | 2,738 | $ | (143 | ) | $ | 2,191 | 15.5 | % | $ | 5.77 | ||||||||||
| Adjusted percent net sales | 65.7 | % | 33.9 | % | 6.4 | % | 25.5 | % | (1.3 | ) | % | 20.4 | % | ||||||||||||||
| (a) | Charges represent certain acquisition and integration-related costs associated with acquisitions. |
| (b) | Charges represent the costs associated with the termination of sales relationships in certain countries, workforce reductions, elimination of product lines, certain long-lived asset impairments and associated costs and other restructuring-related activities. |
| (c) | Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union and China. |
| (d) | Charges represent changes in our best estimate of the minimum end of the range of probable loss to resolve certain recall-related matters. |
| (e) | Our best estimate of the minimum of the range of probable loss to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements. |
| (f) | Benefits and charges represent the accounting impact of certain significant and discrete tax items, including adjustments related to the Tax Cuts and Jobs Act of 2017, and the transfer of certain intellectual properties between tax jurisdictions. |
